Payment overview · 2025
General Payments
$1,326.25
72 reported records · 11 companies
Healthcare provider profile · identity verified
Allison Berus, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ORCHARD PARK, NY · NPI 1295210102
Verified facts
What the public records show
CMS Open Payments records show Allison Berus, PA received $1,326.25 in general payments during 2025 across 72 reported records.
Novo Nordisk Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $233.93 | 17.6% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.78 | 16.9% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $202.87 | 15.3% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.59 | 11.6% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $132.05 | 10.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $110.46 | 8.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.55 | 7.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $84.44 | 6.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.72 | 2.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.11 | 1.7% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $21.75 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,326.25 | 72 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $153.59 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $153.59 | 9 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $141.77 | 8 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $136.79 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $134.81 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.52 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $132.05 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $110.46 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.55 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $84.44 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.44 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $70.26 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.14 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $61.10 | 5 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $60.85 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 134 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
106 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 331 | 126 |
| Lisinopril | Lisinopril | 276 | 111 |
| Omeprazole | Omeprazole | 236 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 181 | 44 |
| Alprazolam | Alprazolam | 171 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 69 |
| Methylprednisolone | Methylprednisolone | 159 | 134 |
| Eliquis | Apixaban | 134 | 40 |
| Gabapentin | Gabapentin | 133 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 61 |
| Simvastatin | Simvastatin | 119 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 112 | 84 |
| Furosemide | Furosemide | 111 | 53 |
| Losartan Potassium | Losartan Potassium | 110 | 42 |
| Synthroid | Levothyroxine Sodium | 106 | 36 |
| Irbesartan | Irbesartan | 103 | 38 |
| Metformin Hcl | Metformin Hcl | 103 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 100 | 36 |
| Ibuprofen | Ibuprofen | 99 | 35 |
| Prednisone | Prednisone | 99 | 61 |
| Atenolol | Atenolol | 91 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 45 |
| Trazodone Hcl | Trazodone Hcl | 86 | 31 |
| Tramadol Hcl | Tramadol Hcl | 81 | 28 |
| Metformin Hcl Er | Metformin Hcl | 77 | 33 |
| Azithromycin | Azithromycin | 76 | 69 |
| Sertraline Hcl | Sertraline Hcl | 76 | 28 |
| Famotidine | Famotidine | 74 | 23 |
| Ozempic | Semaglutide | 72 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 39 |
| Bupropion Xl | Bupropion Hcl | 66 | 27 |
| Jardiance | Empagliflozin | 65 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 20 |
| Celecoxib | Celecoxib | 63 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 27 |
| Ezetimibe | Ezetimibe | 59 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 51 |
| Valsartan | Valsartan | 56 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 18 |
| Pregabalin | Pregabalin | 43 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 17 |
| Valacyclovir | Valacyclovir Hcl | 42 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 33 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Allopurinol | Allopurinol | 34 | 16 |
| Fenofibrate | Fenofibrate | 34 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 11 |
| Cephalexin | Cephalexin | 31 | 23 |
| Diazepam | Diazepam | 31 | 17 |
| Trulicity | Dulaglutide | 31 | 11 |
| Fluocinonide | Fluocinonide | 30 | 22 |
| Lovastatin | Lovastatin | 30 | 11 |
| Naproxen | Naproxen | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 16 |
| Meloxicam | Meloxicam | 27 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 25 |
| Potassium Chloride | Potassium Chloride | 27 | 11 |
| Bumetanide | Bumetanide | 26 | 12 |
| Clonazepam | Clonazepam | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,326.25 · 72 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error